div classBodysc17zpet90 cdBBJodivpReuters – Swiss drugmaker Roches first quarter sales rose 10, driven by drugs including Ocrevus against multiple sclerosis as well as Hemlibra against haemophilia, and on strong U.S. demand for rapid COVID19 antigen tests.
Quarterly sales rose to 16.44 billion Swiss francs 17.17 billion, up from 14.93 billion Swiss francs in the yearearlier period, the company said on Monday. That was slightly above a market consensus of about 16 billion francs.pdivdivdiv classBodysc17zpet90 cdBBJodiv
Roche also confirmed its guidance for 2022.
1 0.9577 Swiss francs
Reporting by Ludwig Burger Editing by Miranda Murray
divdivdiv classBodysc17zpet90 cdBBJodivdivdiv
